An experimental drug cocktail has been found to eradicate Hepatitis C after six weeks of therapy.
Achillion Pharmacutical Inc’s hepatitis C drug, when used together with Gilead Sciences Inc’s Sovaldi, removed viral signs after six weeks.
Related Article: CPhO: ‘Ambition’ to explore weight-loss meds through non-GP routes
This result bettered Gilead’s own hepatitis C treatment which managed the same amount of viral reduction after eight weeks.
Achillion’s ongoing mid-stage study is aiming to achieve a sustained virological response 12 weeks after therapy, which is considered a cure.
It was achieved by using a 50mg dose of Achillion’s NS5a inhibitor in combination with 400mg of Gileads’ sofosbuvir in previously untreated genotype 1 hepatitis C patients.
Related Article: ICB management cuts will exclude pharmacy commissioning
Achillion CEO Milind Deshpande said the data represents the “shortest duration and highest response” achieved with any two drug, direct acting antiviral regime for hepatitis C.
It is claimed hepatitis C affects 150m people worldwide.
Related Article: New training for pharmacists to support veterans
Almost 50% of people who inject drugs in England are believed to have the disease. Hepatitis C is usually transmitted through blood to blood contact - through sharing razors, toothbrushes or sharing unsterilised needles.
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.